Newron Pharmaceuticals SpA ( (CH:NWRN) ) has provided an announcement.
Newron Pharmaceuticals announced the election of Dr. Chris Martin as the new Chairman of the Board during their 2025 General Meeting. The meeting also extended a capital increase until 2028, although some agenda items were not voted on due to a lack of quorum. This leadership change and financial strategy adjustment may influence Newron’s future operations and strategic direction, especially in the context of their ongoing drug development efforts.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company based in Bresso, near Milan, Italy, focusing on developing novel therapies for central and peripheral nervous system disorders. Their lead drug candidate, Evenamide, is in phase III clinical development for treatment-resistant schizophrenia and is noted for its potential as an add-on therapy. The company has a successful track record with CNS therapies, including the Parkinson’s drug Xadago®, which is approved in multiple international markets.
Technical Sentiment Signal: Sell
Current Market Cap: $164.3M
For detailed information about NWRN stock, go to TipRanks’ Stock Analysis page.